BusinessFoundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2ABy Nasdaq OMXFeb 12, 2018, 12:01 PM UTC
BusinessProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic BlindnessBy Nasdaq OMXNov 13, 2017, 12:00 PM UTC
